<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00937651</url>
  </required_header>
  <id_info>
    <org_study_id>A657-BR-CT-201</org_study_id>
    <nct_id>NCT00937651</nct_id>
  </id_info>
  <brief_title>Efficacy, Safety and Pharmacodynamic/Pharmacokinetic Study of Fimasartan (BR-A-657•K)</brief_title>
  <acronym>Fimasartan</acronym>
  <official_title>Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Antihypertensive Efficacy, Safety, Tolerability, and Pharmacodynamic/Pharmacokinetic Profiles After 4 Weeks of Oral Administration of Fimasartan(BR-A-657) at 20-180mg in Patients With Essential Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boryung Pharmaceutical Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boryung Pharmaceutical Co., Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study objective:&#xD;
&#xD;
        1. To evaluate the antihypertensive efficacy, safety and tolerability of the drug after the&#xD;
           oral administration of BR-A-657•K at 20~180mg for 4 weeks to patients with essential&#xD;
           hypertension.&#xD;
&#xD;
        2. To review the pharmacokinetic profile after the multiple administration and the&#xD;
           pharmacodynamic profile regarding the renin-angiotensin system, after the oral&#xD;
           administration of BR-A-657•K at 20~180mg for 4 weeks to patients with essential&#xD;
           hypertension.&#xD;
&#xD;
        3. To determine the dose for the clinical study at the next phase by analyzing the&#xD;
           relationship between the antihypertensive efficacy and pharmacokinetic • pharmacodynamic&#xD;
           results.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Fimasartan (BR-A-657-K), a selective blocker of AT1 receptor subtype, showed the rapid and&#xD;
      potent antihypertensive effect in many hypertensive models. Phase I study, Fimasartan&#xD;
      (BR-A-657-K) 20mg ~ 480mg single dosing with healthy subjects, demonstrated that the&#xD;
      Fimasartan (BR-A-657-K) was very safe and well tolerated. Another phase I study, Fimasartan&#xD;
      (BR-A-657-K) 120mg and 360mg dosing for 7 days, also showed that Fimasartan (BR-A-657-K) was&#xD;
      safe and tolerable though one temporal adverse event was observed in high dose.&#xD;
&#xD;
      A randomized, double-blind, placebo-controlled, parallel grouped, clinical study will be&#xD;
      conducted to evaluate the antihypertensive efficacy and tolerability and to determine&#xD;
      adequate antihypertensive dosage of Fimasartan(BR-A-657-K) in patients with mild to moderate&#xD;
      essential hypertension.&#xD;
&#xD;
      Approximately 60 patients will be enrolled over 12 months in Seoul National University&#xD;
      Hospital.&#xD;
&#xD;
      After 2 weeks of placebo run-in period, all subjects will be randomized into one of the&#xD;
      following 5 groups. Subjects will take test drug/placebo for 28 days of treatment period. If&#xD;
      subjects take any antihypertensive medications before screening, the subjects will have 1&#xD;
      week of wash-out period.&#xD;
&#xD;
      Group I : Placebo, Group II : Fimasartan 20 mg, Group III: Fimasartan 60 mg, Group IV :&#xD;
      Fimasartan 180 mg&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2005</start_date>
  <completion_date type="Actual">June 2006</completion_date>
  <primary_completion_date type="Actual">June 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the level of sitting diastolic blood pressure reduction</measure>
    <time_frame>Day -1 vs Day 27</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>the level of sitting systolic blood pressure reduction, mean blood pressure (MBP), 24-hr day-time, night-time SBP and DBP, T/P ratio based on the 24-hr Ambulatory Blood Pressure Monitoring</measure>
    <time_frame>Day -1 vs Day 27</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">81</enrollment>
  <condition>Essential Hypertension</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, 3 tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BR-A-657•K 20 mg group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fimasartan 20 mg, 1 tablet + placebo, 2 tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BR-A-657•K 60 mg group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fimasartan 20 mg, 1 tablet + 40 mg, 1 tablet + placebo 1 tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BR-A-657•K 180 mg group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fimasartan 20 mg, 1 tablet + 80 mg, 1 tablet + 80 mg 1 tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fimasartan (BR-A-657•K) 20 mg</intervention_name>
    <description>Fimasartan 20 mg, 1 tablet + placebo, 2 tablets</description>
    <arm_group_label>BR-A-657•K 20 mg group</arm_group_label>
    <other_name>Fimasartan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fimasartan (BR-A-657•K) 60 mg</intervention_name>
    <description>Fimasartan 20 mg, 1 tablet + 40 mg, 1 tablet + placebo 1 tablet</description>
    <arm_group_label>BR-A-657•K 60 mg group</arm_group_label>
    <other_name>Fimasartan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fimasartan (BR-A-657•K) 180 mg</intervention_name>
    <description>Fimasartan 20 mg, 1 tablet + 80 mg, 1 tablet + 80 mg 1 tablet</description>
    <arm_group_label>BR-A-657•K 180 mg group</arm_group_label>
    <other_name>Fimasartan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult men and women, aged 18 - 65&#xD;
&#xD;
          -  Patients with mild to moderate essential hypertension: On both screening and Day -1&#xD;
             visit, mean sitting DBP should be ≥ 95mmHg and ≤ 114mmHg, and ΔDBP on Day -14 and Day&#xD;
             -1 should be within 7 mmHg&#xD;
&#xD;
          -  Patients who gave their consent to participate in this study and signed the written&#xD;
             informed consent form&#xD;
&#xD;
          -  Patients who have understood the study, and been judged to be cooperative and able to&#xD;
             participate in the study until the study completion date&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Women of childbearing potential who have not received the hysterectomy or men who are&#xD;
             not willing to use birth control measures.&#xD;
&#xD;
          2. Patients whose sitting DBP is &lt; 95mmHg or ≥ 115mmHg. Patients with severe hypertension&#xD;
             whose SBP is ≥200mmHg&#xD;
&#xD;
          3. Patients with secondary hypertension&#xD;
&#xD;
          4. Patients with severe renal disease, gastrointestinal disorder, hematologic disorder,&#xD;
             liver disease, etc. that can affect the absorption, distribution, metabolism and&#xD;
             excretion of drugs&#xD;
&#xD;
          5. Patients with symptoms of orthostatic hypotension&#xD;
&#xD;
          6. Patients with severe insulin dependent diabetes or uncontrolled diabetes&#xD;
&#xD;
          7. Patients who suffered myocardial infarction or serious coronary arterial disease over&#xD;
             the past 6 months or patients with clinically significant congestive heart failure or&#xD;
             valvular heart disease&#xD;
&#xD;
          8. Patients with consumption disease, autoimmune disease, or connective tissue disease&#xD;
&#xD;
          9. Patients with the history of type B hepatitis or type C hepatitis&#xD;
&#xD;
         10. Patients with HIV infection or hepatitis&#xD;
&#xD;
         11. Patients with clinically significant abnormal laboratory test findings&#xD;
&#xD;
         12. Patients on any drug treatment that might affect the blood pressure&#xD;
&#xD;
         13. Patients with allergy or contraindication to angiotensin II-receptor antagonists&#xD;
&#xD;
         14. Patients with current or suspected alcohol addiction or history of drug abuse&#xD;
&#xD;
         15. Patients whose mean weight lies out of the range of -15% ~ +35%, based on the Modified&#xD;
             Metropolitan Life Insurance table&#xD;
&#xD;
         16. Patients who are not eligible as subjects of the study, as determined by the principal&#xD;
             investigator or a sub-investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>July 2009</verification_date>
  <study_first_submitted>July 10, 2009</study_first_submitted>
  <study_first_submitted_qc>July 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 13, 2009</study_first_posted>
  <last_update_submitted>July 10, 2009</last_update_submitted>
  <last_update_submitted_qc>July 10, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 13, 2009</last_update_posted>
  <responsible_party>
    <name_title>Choi, Jeongeun / Director</name_title>
    <organization>Boryung Pharmaceutical Co., Ltd</organization>
  </responsible_party>
  <keyword>Fimasartan</keyword>
  <keyword>Essential Hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Essential Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

